Market Snapshot
S&P Futures
3,809.5
Dow Futures
30,868
Nasdaq Futures
11,633.25
ERYTECH Pharma S.A. (ERYP) stock declined over - intraday to trade at $1.12 a share on NASDAQ. The stock opened with a gain of 8.74% at $1.12 and touched an intraday high of $1.12, falling -0.00% against the last close of $1.12. The stock went to a low of $1.07 during the session.
Prev. Close
Market Cap
Day Low
Open
Number of Shares
Day High
P/E ratio
EPS (TTM)
Cash Flow per Share
Free Float in %
Book Value
Volume
Date | Open | High | Low | Close | Volume |
---|---|---|---|---|---|
2022-06-30 | $1.12 | $1.12 | $1.07 | $1.095 | 1,294 |
2022-06-29 | $1.03 | $1.12 | $1.03 | $1.12 | 700 |
2022-06-28 | $1.15 | $1.16 | $1.01 | $1.14 | 5,500 |
2022-06-27 | $1.246 | $1.246 | $1.07 | $1.15 | 4,800 |
2022-06-24 | $1.143 | $1.143 | $1.105 | $1.13 | 6,900 |
2022-06-23 | $1.03 | $1.198 | $1.03 | $1.13 | 15,500 |
2022-06-22 | $1.1 | $1.1 | $1.07 | $1.1 | 14,900 |
2022-06-21 | $1.03 | $1.12 | $1.03 | $1.11 | 17,500 |
2022-06-17 | $1.01 | $1.06 | $0.98 | $1.06 | 14,200 |
2022-06-16 | $1.04 | $1.069 | $1.03 | $1.069 | 6,700 |
Employees-
Beta2.01
Sales or Revenue4.18 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
SectorHealth Care
IndustryBiotechnology
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
ERYTECH Pharma S.A. (NASDAQ: ERYP) stock price is $1.12 as of the last check on Thursday, June 30. During the trading session, ERYP stock reached the peak price of $1.12 while $1.07 was the lowest point it dropped to.
The NASDAQ listed ERYP is part of Biotechnology industry that operates in the broader Health Care sector. ERYTECH Pharma S. A.
Mr. Jean-Sebastien Cleiftie M.B.A., M.S.
Chief Bus. Officer
Mr. Gil Beyen BVBA
CEO & Director
Mr. Eric Soyer Ph.D.
CFO, COO & Deputy GM
Dr. Jérôme Bailly Pharm.D.
Deputy GM of Operations, Chief Quality Officer & Qualified Person
ERYP stock traded closed the last session at $1.095, which is $0.00 or - lower than its previous close of $1.12. ERYP's current trading price is 14.27% lower than its 52-week high of $9.50 where as its distance from 52-week low of 0.98% is -88.21%.
Number of ERYP employees currently stands at -. ERYP operates from 60 Avenue Rockefeller, Lyon 69008, France.
Official Webiste of $ERYP is: https://www.erytech.com
ERYP could be contacted at ERYP operates from 60 Avenue Rockefeller, Lyon 69008, France, or at phone #33 4 78 74 44 38 and can also be accessed through its website.
ERYP stock volume for the day was 1,294 shares while in the previous session number of ERYP shares traded was 1,294 . The average number of ERYP shares traded daily for last 3 months was 928.95 Thousands.
The percentage change in ERYP stock occurred in the recent session was - while the dollar amount for the price change in ERYP stock was $0.00.
In the recent session, the day high for ERYP stock was $1.12 while the low for ERYP stock touched on the day was $1.07.
The market value of ERYP currently stands at 37.07 Million with its latest stock price at $1.12 and 31.02 Million of its shares outstanding.